undamentalytics Newsletter
Sign in

Artelo Biosciences, Inc. (ARTL) stock

Add to watchlist

Add holding +

NASDAQ: ARTL Nasdaq Biotechnology

Artelo Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds7 adding, 4 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 131.5% while net income fell 20.6%: a 111pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Artelo Biosciences, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Share dilution. Diluted shares rose 11.0% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 281% and a beta of -1.9 against the S&P 500.
  • Short interest rising. Shares sold short rose 54% in a month to 6.3% of tradable shares.

Latest results

Earnings per share
-$0.12 against an average estimate of -$4.71: beat by 97.4%
Share reaction
+76.1% in the first session after the results on March 17, 2026, against -1.1% for the S&P 500

Artelo Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.3%
  • 1 week-1.4%
  • 1 month-41.0%
  • This year-93.4%
  • 1 year-97.4%
  • 5 years-99.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
March 17, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Shareholder vote

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Artelo Biosciences, Inc. valuation models and calculator

No model value for Artelo Biosciences, Inc. at the moment. Current status: share count (1m) is 0.15x the cover-page count (5m). Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: share count (1m) is 0.15x the cover-page count (5m): held for review.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Artelo Biosciences, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Dec 2025 −$4.71 −$0.12 +97.4%
Jun 2025 −$12.57 −$16.83 −33.9%
Mar 2025 −$2.34 −$12.96 −453.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
6.3%
of tradable shares
Days to cover
0.03
at average volume
Short interest, 1 month
+54%
to October 15, 2026
Held by institutions
2%
of shares
Held by insiders
0.1%
of shares
Employees
7
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ARTL−29%−63%−52%−24%−81%−93%
Industry peers (median)−36%−56%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ARTL17%25%42%33%33%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ARTL−83%−72%−65%−45%−96%−98%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 21, 2019: 100% from June 24, 2019 to November 2, 2026. Getting back needed a 551969% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.17 – $94.86
From 52-week high
−97.7%
vs 50-day average
−48.4%
vs 200-day average
−89.9%
Volatility (1 year)
281%
Beta vs S&P 500
-1.92

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 3 down
typical move ±34.4%
After a week
1 up, 3 down
typical move ±28.8%
After a month
1 up, 3 down
typical move ±38.5%
Results releasedNext dayS&P 500 next day5 days21 days
March 17, 2026 +76.1% −1.1% +39.5% +17.1%
July 11, 2025 −34.9% −0.2% −47.5% −64.8%
January 14, 2020 −15.8% +0.1% −12.3% −47.1%
July 15, 2019 −10.6% −0.3% −15.8% −24.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-KT, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$131,972
Institutions reporting
10
Shares held vs prior quarter
▲ 156.8%
Positions opened / closed
5 / 4

Top buyers and sellers, Q2 2026: 7 institutions bought and 4 sold ; the biggest buyer was Jane Street Group, LLC (+53K shares) and the biggest seller Kathmere Capital Management, LLC (−13K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jane Street Group, LLC $74,302 66K 56.3% ▲ 407.2%
Geode Capital Management, LLC $15,526 14K 11.8% New
Stonex Group Inc. $14,692 12K 11.1% New
Vanguard Capital Management LLC $11,344 10K 8.6% 0.0%
Tower Research Capital LLC (TRC) $9,447 8K 7.2% ▲ 198.5%
Vanguard Fiduciary Trust Co $3,516 3K 2.7% 0.0%
UBS Group AG $3,140 3K 2.4% New
Rothschild Investment LLC $2 0K 0.0% 0.0%
TD Waterhouse Canada Inc. $2 0K 0.0% New
Danske Bank A/S $1 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Artelo Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • March 17, 2026
  • July 11, 2025
  • January 14, 2020
  • July 15, 2019

Recent SEC filings

Data status

When each part of this page on Artelo Biosciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Artelo Biosciences, Inc. in brief

What does Artelo Biosciences, Inc. do?
Artelo Biosciences, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Artelo Biosciences, Inc.'s stock ticker?
Artelo Biosciences, Inc. trades under the ticker ARTL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Artelo Biosciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jane Street Group, LLC, Geode Capital Management, LLC and Stonex Group Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.